A posttranslational modification cascade drives RAS-induced senescence
Cancer Discovery
|July 13, 2013
Abstract:
Posttranslational modifications of TIP60 and PRAK mediate oncogenic RAS-induced senescence.
Insights
Oncogenic RAS proteins trigger cellular senescence, a tumor-suppressive mechanism. This study reveals that posttranslational modifications of TIP60 and PRAK are crucial for mediating this RAS-induced senescence.
Area of Science:
- Molecular oncology
- Cellular senescence
- Cancer biology
Background:
- Oncogenic RAS mutations are common drivers of cancer.
- Cellular senescence is a critical tumor-suppressive mechanism that can be induced by oncogenic stress.
- The precise molecular mechanisms linking oncogenic RAS to senescence induction are not fully elucidated.
Purpose of the Study:
- To investigate the role of posttranslational modifications in mediating oncogenic RAS-induced senescence.
- To identify key proteins involved in the senescence response to oncogenic RAS.
- To elucidate the functional significance of TIP60 and PRAK modifications in this context.
Main Methods:
- Utilized cell culture models with oncogenic RAS expression.
- Employed techniques such as Western blotting, immunoprecipitation, and immunofluorescence to assess protein modifications.
- Performed senescence assays, including SA-β-gal staining and cell cycle analysis.
- Investigated the impact of genetic or pharmacological inhibition of TIP60 and PRAK.
Main Results:
- Demonstrated that oncogenic RAS induces specific posttranslational modifications on TIP60 and PRAK.
- Showed that these modifications are essential for the establishment and maintenance of senescence.
- Found that impaired TIP60 or PRAK modification abrogates RAS-induced senescence, promoting cell proliferation.
- Identified TIP60 and PRAK as critical mediators in the cellular response to oncogenic RAS.
Conclusions:
- Posttranslational modifications of TIP60 and PRAK are key regulatory events in oncogenic RAS-induced senescence.
- Targeting these modifications could represent a novel therapeutic strategy to restore tumor suppression in RAS-driven cancers.
- This study provides new insights into the molecular pathways governing senescence as a barrier to cancer development.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...